Clinical trial
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity…
NCT00418483 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00418483 |
|---|---|
| Title | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion |
| Official title | A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion |
| Acronym | PRIORITY |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Arterial Occlusive Diseases |
| Intervention type | Biological |
| Interventions | Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg |
| Enrollment | 83 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Jan 4, 2007 |
| Last update posted | Oct 31, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: